A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies.
Latest Information Update: 15 Oct 2012
At a glance
- Drugs Temsirolimus (Primary) ; Topotecan (Primary)
- Indications Gynaecological cancer
- Focus Adverse reactions
- 25 Apr 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 25 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.